imm-1-104 Our lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers.

Dec 1, 2021 · IMM-1-104 is a novel dual-MEK inhibitor that is designed to disrupt phosphorylation of MEK and subsequently prevent activation of ERK1 and ERK2 (ERK). IMM-1-104’s dual-MEK mechanism resists RAF activation of MEK, and its short drug half-life allows for chronic dosing while maintaining a near-zero drug trough for improved tolerability.

IMM-1-104, a novel MEK inhibitor, blocks both MEK and ERK phosphorylation preventing CRAF bypass and hyperactivation of MEK. A short half-life of 2 hours combined with once daily dosing (QD) drives deep, pulsatile inhibition of the MAPK pathway at MEK in a process called Deep Cyclic Inhibition (DCI).

Jun 5, 2023 · IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of the MAPK pathway with once-daily oral dosing.

Jan 20, 2025 · In second-line pancreatic cancer, IMM-1-104 monotherapy achieved disease control in 11 of 21 patients, with rash as the most common side effect. Immuneering plans to expand phase 2a trials with new combination arms, targeting BRAF-mutant melanoma and non-small cell lung cancer.

A head-to-head comparison in vivo demonstrated no Tumor Growth Inhibition (TGI) by sotorasib and adagrasib in KRAS-G12V mutant Capan-2 PDAC tumors, while IMM-1-104 prompted TGIs of 49 to 84% across all doses and schedules tested.

Apr 9, 2024 · IMM-1-104 showed promising combination effects when treated with gemcitabine (GEM), paclitaxel (PAC) or fluorouracil (5FU) in 3D-tumor growth assay (TGA) pancreatic cancer models. IMM-1-104 was synergistic with chemotherapy in animal models of pancreatic cancer.

Feb 21, 2024 · IMM-1-104–an investigational drug with a novel mechanism–targets the MAPK pathway, aiming to effectively inhibit the growth of these cancers. By specifically targeting cancer cells, it minimizes impact on healthy cells.

Early Phase 1/2a Dose Escalation IMM-1-104 Clinical Trial Summary •Clinical data timeline reported through April 10 th , 2023 (i.e., 20 weeks since first patient dosed) •Actively enrolling patients at 320 mg QD p.o. with 2 additional patients already consented (KRAS-G12V Pancreatic and KRAS-G12S Colorectal)

Oct 15, 2024 · IMM-1-104 has shown promising results in pancreatic cancer, with a 40% ORR and 80% DCR in initial phase 2a data. The FDA granted orphan drug designation and fast track status to IMM-1-104 for...